

**Curriculum Vitae**  
Tracy G. Lively, Ph.D.

Business Address: 9609 Medical Center Drive, MSC 9730  
Rockville, MD 20892  
240-276-5944 (tel), 240-276-7889 (fax)  
livelyt@mail.nih.gov (e-mail)

**EDUCATION AND PROFESSIONAL EXPERIENCE:**

- 2016-present Chief, Diagnostics Evaluation Branch, DCTD, National Cancer Institute
- 2011-present Deputy Associate Director, Cancer Diagnosis Program, DCTD, National Cancer Institute
- 2004-2011 Associate Chief, Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute
- 1996-2004 Program Director, Diagnostics Research Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute
- 1990-1996 Assistant Professor, Division of Biomedical Sciences, University of California, Riverside, CA.
- 1989-1990 Senior Associate, Howard Hughes Medical Institute, University of California, Los Angeles, CA. Supervisor: Dr. O.N. Witte
- 1987-1989 Postdoctoral Fellow, UCLA Intercampus Medical Genetics Training Program and Department of Microbiology. University of California, Los Angeles, California. Sponsor: Dr. O.N. Witte
- 1982-1987 Postdoctoral Fellow, USC Comprehensive Cancer Center and Department of Microbiology, School of Medicine, University of Southern California, Los Angeles, California. Sponsor: Dr. R.E.K. Fournier.
- 1976-1982 Graduate Student, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts. Advisor: Dr. R.M. Baker.
- 1975 Participant, NSF Undergraduate Research Participation Program, Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut. Advisor: Dr. J. Cronan.
- 1972-1976 Pomona College, Claremont, California.

## **HONORS:**

7/85-6/87 Hereditary Disease Foundation Fellow  
7/83-6/85 Leukemia Society of America Fellow  
6/83 Member, Sigma Xi  
3/82-2/83 NIH Postdoctoral Traineeship  
9/79-2/82 NIH Predoctoral Traineeship  
9/76-8/79 NSF Graduate Fellowship  
6/76 Phi Beta Kappa  
6/76 Magna Cum Laude with Vail Prize in Zoology, Pomona College

## **PROFESSIONAL SOCIETIES:**

American Association for Cancer Research  
Association for Molecular Pathology  
Society for Neuro-Oncology  
American Society of Clinical Oncology

## **PUBLICATIONS:**

Gross, T.A. Gene Transfer into Cultured Human Cells, Ph.D. dissertation, Massachusetts Institute of Technology, February 26, 1982.

Lugo, T.G. and R.M. Baker. Chromosome-mediated Gene Transfer of HPRT and APRT in an Intra-specific Human Cell System. Somatic Cell Genet. 9: 175-188 (1983).

Killary, A.M., T.G. Lugo and R.E.K. Fournier. Isolation of Thymidine Kinase-Deficient Rat Hepatoma Cells by Selection with Bromodeoxyuridine, Hoechst 33258, and Visible Light. Biochemical Genetics 22: 201-213 (1984).

Wynshaw-Boris, A., T.G. Lugo, J.M. Short, R.E.K. Fournier and R.W. Hanson. Identification of a cAMP Regulatory Region in the Gene for Rat Cytosolic Phosphoenolpyruvate Carboxykinase (GTP): Use of Chimeric Genes Transfected into Rat Hepatoma Cells. J. Biol. Chem. 259: 12161-12169 (1984).

Lugo, T.G. and R.M. Baker. Chromosome-mediated Transfer of Murine Alleles for HGPRT and Ouabain-resistance into Human Cell Lines. Biochemical Genetics 23: 1-15 (1985).

Wynshaw-Boris, A., T.G. Lugo, J.M. Short, R.E.K. Fournier and R.W. Hanson. A Region of the Gene for Rat Cytosolic Phosphoenolpyruvate Carboxykinase (GTP) Confers cAMP Responsiveness to the Herpes Simplex Virus Thymidine Kinase Gene. In Membrane Receptors and Cellular Recognition, Michael P. Czech and C. Ronald Kahn, eds., Alan R. Liss, New York, pp. 339-346 (1985).

Lugo, T.G. and R.E.K. Fournier. Microcell Fusion and Mammalian Gene Transfer. In Gene Transfer, R. Kucherlapati, ed., Plenum Press, New York, pp. 79-93 (1986).

Lugo, T.G., R. Leach and R.E.K. Fournier. Parasexual Approaches to the Study of Human Genetic Disease. Ann. N.Y. Acad. Sci. 486: 293-303 (1986).

Lugo, T.G., B. Handelin, A.M. Killary, D.E. Housman and R.E.K. Fournier. Isolation of Microcell Hybrid Clones Containing Retroviral Vector Insertions into Specific Human Chromosomes. Mol. Cell. Biol. 7: 2814-2820 (1987).

Cheng, S.V., T.G. Lugo, R.E. Tanzi, J.B. Whitney, R.E.K. Fournier, and J.F. Gusella. Chromosomal localization of the mouse homolog of the Huntington's disease linked G8 (DS4S10) marker. Dna 6: 401-407 (1987).

Blatt, C., P. Eversole-Cire, V.H. Cohn, S. Zollman, R.E.K. Fournier, L.T. Mohandas, M. Nesbitt, T. Lugo, D.T. Jones, R.R. Reed, L.P. Weiner, R.S. Sparkes and M.I. Simon. Chromosomal localization of genes encoding guanine nucleotide-binding protein subunits in mouse and human. Proc. Natl. Acad. Sci. USA 85: 7642-7646 (1988).

Lugo, T.G. and O.N. Witte. The BCR-ABL Oncogene Transforms Rat 1 Cells and Co-operates with v-myc. Mol. Cell. Biol. 9: 1263-1270 (1989).

Lugo, T.G. and O.N. Witte. The BCR-ABL protein of Philadelphia chromosome-positive leukemias. In Molecular Approaches to the Study and Treatment of Philadelphia Chromosome Positive Leukemia. A.B. Deisseroth and R.B. Arlinghaus, eds., Marcel Dekker, New York. (1990).

Thayer, M.J., T.G. Lugo, R.J. Leach and R.E.K. Fournier. Regulation of Chimeric Phosphoenolpyruvate Carboxykinase Genes by the trans-Dominant Locus Tse-1. Mol. Cell. Biol. 10: 2660-2668 (1990).

Lugo, T.G., A.M. Pendergast, A.J. Muller and O.N. Witte. Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products. Science 247: 1079-1082 (1990).

Coleman, A.C., J.W. Fountain, T. Nobori, O.I. Olopade, G. Robertson, D.E. Housman and T.G. Lugo. Distinct deletions of chromosome 9p associated with melanoma *versus* glioma, lung cancer and leukemia. Cancer Research 54:344-348 (1993).

Blackwood, E.M., T.G. Lugo, L. Kretzner, M.W. King, A.J. Street, O.N. Witte, and R.N. Eisenman. Functional analysis of the AUG- and CUG-Initiated Forms of the c-Myc Protein. Mol. Biol. Cell 5:597-609 (1994).

Coleman, A., G. Robertson and T.G. Lugo. Growth control by tumor suppressors in malignant melanoma. Receptor 5:9-19 (1995).

Robertson, G., A. Coleman and T.G. Lugo. Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6. Cancer Research 56:1635-1641 (1996).

Miele, M.E., G. Robertson, J.-H. Lee, A. Coleman, C.T. McGary, P.B. Fisher, T.G. Lugo and D.R. Welch. Metastasis is suppressed in human melanoma cell line MelJuSo following introduction of human chromosomes 1 or 6 but tumorigenicity and local invasiveness are unaffected. Molecular Carcinogenesis 15: 284-299 (1996).

Rooney, R.D., W.E. Meek, P.T. Tuazon, E.J. Carroll, Jr., J.J. Hagen, E.L. Gump, C.A. Monnig, T. Lugo and J.A. Traugh. Cleavage arrest in early frog embryos by the G protein-activated protein kinase PAK I. Journal of Biological Chemistry 35:21498-21504 (1996).

Robertson, G., A. Coleman and T.G. Lugo. A malignant melanoma tumor suppressor on human chromosome 11. Cancer Research 56:4487-4492 (1996).

Robertson, G.P., A. Hufford and T.G. Lugo. A Panel of Transferable Fragments of Human Chromosome 11q. Cytogenetics and Cell Genetics 79:53-59 (1997).

Coleman, A.B., and T.G. Lugo. Normal human melanocytes that express a bFGF transgene still require exogenous bFGF for growth in vitro. J. Invest. Dermatol. 110:793-799 (1998).

Robertson, G.P., F.B. Furnari, M.E. Miele, M.J. Glendening, D.R. Welch, J.W. Fountain, T.G. Lugo, H.J. Huang and W.K. Cavenee. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl. Acad. Sci. USA 95:9418-9423 (1998).

Robertson, G.P., E.K. Goldberg, T.G. Lugo and J.W. Fountain. Functional localization of a melanoma tumor suppressor gene to a small (< or = 2 Mb) region on 11q23. Oncogene 18:3173-3180 (1999).

Ivy, S.P., T.G. Lugo, M.L. Bernstein and M.A. Smith. Evolving Molecular and Targeted Therapies. In Principles and Practice of Pediatric Oncology, Fourth Edition, pp. 309-349. P.A. Pizzo and D.G. Poplack eds. Lippincott Williams and Wilkins, Philadelphia (2002).

Lugo, T.G., S. Braun, R.J. Cote, K. Pantel and V. Rusch. Detection and Measurement of Occult Disease for the Prognosis of Solid Tumors. J. Clin. Oncol. 21:2609-2615 (2003).

Taube, S.E., J.W. Jacobson and T.G. Lively. Cancer Diagnostics: Decision Criteria for Marker Utilization in the Clinic. Am. J. Pharmacogenomics 5:357-364 (2005).

Jessup, J.M., T.G. Lively and S.E. Taube. Program for the Assessment of Clinical Cancer Tests (PACCT): implementing promising assays into clinical practice. Expert Rev. Mol. Diagn. 5: 271-273 (2005).

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma: Shedden, K. et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine 14: 822-827 (2008).

Dowsett, M., T.O. Nielsen, R. A'Hern, J. Bartlett, R. C. Coombes, J. Cuzick, M. Ellis, N.L. Henry,

J.C. Hugh, T. Lively, L. McShane, S. Paik, F. Penault-Llorca, L. Prudkin, M. Regan, J. Salter, C. Sotiriou, I.E. Smith, G. Viale, J.A. Zujewski and D.F. Hayes. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 103:1656-1664 (2011).

Williams, P.M., T.G. Lively, J.M. Jessup and B.A. Conley. Bridging the gap: Moving predictive and prognostic assays from research to clinical use. Clin. Cancer Res. 18:1531-1539 (2012).

McShane, L. M., M. M. Cavenagh, T. G. Lively, D. A. Eberhard, W. L. Bigbee, P. M. Williams, J. P. Mesirov, M. Y. Polley, K. Y. Kim, J. V. Tricoli, J. M. Taylor, D. J. Shuman, R. M. Simon, J. H. Doroshow, and B. A. Conley. Criteria for the Use of Omics-Based Predictors in Clinical Trials. Nature 502:317-20 (2013).

McShane, L. M., M. M. Cavenagh, T. G. Lively, D. A. Eberhard, W. L. Bigbee, P. M. Williams, J. P. Mesirov, M. Y. Polley, K. Y. Kim, J. V. Tricoli, J. M. Taylor, D. J. Shuman, R. M. Simon, J. H. Doroshow, and B. A. Conley. Criteria for the Use of Omics-Based Predictors in Clinical Trials: Explanation and Elaboration. BMC Medicine 11:220-241 (2013).

Hall, J. A., R. Salgado, T. Lively, F. Sweep, and A. Schuh. A Risk-Management Approach for Effective Integration of Biomarkers in Clinical Trials: Perspectives of an NCI, NCRI, and EORTC Working Group. The Lancet Oncology 15: e184-93 (2014).

Lively, T.G., M.C. Sachs and B.A. Conley. Translating Promising Biomarkers into Clinical Oncology Practice. Oncology and Hematology Review 11:14-18 (2015).

Sparano, J.A., R.J. Gray, D.F. Makower, K.I. Pritchard, K.S. Albain, D.F. Hayes, C.E. Geyer, Jr., E.C. Dees, E.A. Perez, J.A. Olson, Jr., J. Zujewski, T. Lively, S.S. Badve, T. J. Saphner, L.I. Wagner, T.J. Whelan, M.J. Ellis, S. Paik, W.C. Wood, P. Ravdin, M.M. Keane, H.L. Gomez Moreno, P.S. Reddy, T.F. Goggins, I.A. Mayer, A. M. Brufsky, D.L. Toppmeyer, V.G. Kaklamani, J.N. Atkins, J.L. Berenberg, and G.W. Sledge. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N. Engl. J. Med. 373:2005-14 (2015).

McShane, L.M., T.G. Lively and H.M. Makhlof. Translation of Biomarkers into Clinical Practice. In: Molecular Pathology of Breast Cancer, pp. 1-18. S. Badve and Y. Gökmen-Polar, eds., Springer (2016).

Sorg, B.S., S. Memnon, K.Y. Kim, A. Ganguly, T. Lively, J. Tricoli, M. Thurin, L. Agrawal, T.C. McKee, B.A. Conley and J.M. Jessup. Predictive Markers and Driver Genes from Treatment Trials: Potential Utility for Early Diagnosis. In: Biomarkers in Cancer Screening and Early Detection, pp. 231-244. S. Srivastava, ed. John Wiley and Sons, (2017).

Salgado, R., H. Moore, J.W.M Martens, T. Lively, S. Malik, U. McDermott, S. Michiels, J.A. Moscow, S. Tejpar, T. McKee, D. Lacombe and IBCD-Faculty. Societal Challenges of Precision Medicine: Bringing Order to Chaos. Eur. J. Cancer. 84:325-334 (2017).

Salgado, R., H. Moore, J.W.M Martens, T. Lively, S. Malik, U. McDermott, S. Michiels, J.A. Moscow, S. Tejpar, T. McKee, D. Lacombe and IBCD-Faculty. Steps Forward for Cancer Precision

Medicine. Nat. Rev. Drug Discov. 17:1-2 (2018).

Morfouace, M., S.M. Hewitt, R. Salgado, K. Hartmann, S. Litiere, S. Tejpar, V. Golfinopoulos, T. Lively, M. Thurin, B. Conley, and D. Lacombe. A Trans-Atlantic Perspective on the Integration of Immuno-Oncology Prognostic and Predictive Biomarkers in Innovative Clinical Trial Design. Semin. Cancer Biol. DOI: 10.106/j.semcancer.2018.01.003 (2018).

Sparano, J.A., R.J. Gray, D.F. Makower, K.I. Pritchard, K.S. Albain, D.F. Hayes, C.E. Geyer, Jr., E.C. Dees, M.P. Goetz, J.A. Olson, Jr., T. Lively, S.S. Badve, T. J. Saphner, L.I. Wagner, T.J. Whelan, M.J. Ellis, S. Paik, W.C. Wood, P. Ravdin, M.M. Keane, H.L. Gomez Moreno, P.S. Reddy, T.F. Goggins, I.A. Mayer, A. M. Brufsky, D.L. Toppmeyer, V.G. Kaklamani, J.L. Berenberg, J. Abrams and G.W. Sledge. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N. Engl. J. Med. 379:111-121 (2018).

Yee, L.M., T.G. Lively and L.M. McShane. Biomarkers in Early-Phase Trials: Fundamental Issues. Bioanalysis. 10:933-944 (2018).

Ossandon, M.R., L. Agrawal, E.J. Bernhard, B.A. Conley, S.M. Dey, R.L. Divi, P. Guan, T.G. Lively, T.C. McKee, B.S. Sorg and J.V. Tricoli. Circulating Tumor DNA Assays in Clinical Cancer Research. J. Natl. Cancer Inst. DOI: 10.1093/jnci/djy105 (2018).

Srivastava, S., S. Ghosh, J. Kagan, R. Mazurchuk, and the National Cancer Institute's HTAN Implementation Team. The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. Trends Cancer. 4:523-536 (2018).

Freedman, A.N., C.N. Klabunde, K. Wiant, L. Enewold, S.W. Gray, K.K. Filipinski, N.L. Keating, D.G.B. Leonard, T. Lively, T.S. McNeel, L. Minasian, A.L. Potosky, D.R. Rivera, R.L. Schilsky, D. Schrag, N.I. Simonds, H.M.Sineshaw, J.P. Struewing, G. Willis and J.S. de Moor. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precision Oncology, DOI: 10.1200/PO.18.00169 JCO Precision Oncology - published online November 13, 2018 (2018).

Salgado, R., D.B. Solit, D.L. Rimm, J. Bogaerts, R. Canetta, T. Lively, K. Lyerly, P.N. Span, A. Bateman-House, A. Makady, L. Bergmann, S. Nagai, C. Smith, M. Robson, M. Savage, E. Voest, C. Sweeney, P. Lambin, M. Thomas, L. Harris, D. Lacombe, C. Massard, on behalf of the IBCD Faculty. Addressing the Dichotomy Between Individual and Societal Approaches to Personalised Medicine in Oncology. Eur. J. Cancer. 114:12-136 (2019).

Sparano, J.A., R.J. Gray, D.F. Makower, K.S. Albain, T.J. Saphner, S.S. Badve, L.I. Wagner, V.G. Kaklamani, M.M. Keane, H.L. Gomez, P.S. Reddy, T.F. Goggins, I.A. Mayer, D.L. Toppmeyer, A.M. Brufsky, M.P. Goetz, J.L. Berenberg, C. Mahalcioiu, C. Desbiens, D.F. Hayes, E.C. Dees, C.E. Geyer, J.A. Olson, W.C. Wood, T. Lively, S. Paik, M.J. Ellis, J. Abrams and G.W. Sledge. Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TailorX Randomized Clinical Trial. JAMA Oncology doi: 10.1001/jamaoncol.2019.4794 (2019)

Sparano, J.A., R.J. Gray, P.M. Ravdin, D.F. Makower, K.I. Pritchard, K.S. Albain, D.F. Hayes, C.E.

Geyer Jr., E.C. Dees, M.P. Goetz, J.A. Olson Jr., T. Lively, S.S. Badve, T.J. Saphner, L.I. Wagner, T.J. Whelan, M.J. Ellis, S. Paik, W.C. Wood, M.M. Keane, H.L. Gomez Moreno, P.S. Reddy, T.F. Goggins, I.A. Mayer, A.M. Brufsky, D.L. Toppmayer, V.G. Kaklamani, J.L. Berenberg, J. Abrams, G.W. Sledge Jr. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. *N. Engl. J. Med.* 380: 2395-2405 (2019).

Rozenblatt-Rosen O., Regev A., Oberdoerffer P., Nawy T., Hupalowska A., Rood J.E., Ashenberg O., Cerami E., Coffey R.J., Demir E., Ding L., Esplin E.D., Ford J.M., Goecks J., Ghosh S., Gray J.W., Guinney J., Hanlon S.E., Hughes S.K., Hwang E.S., Iacobuzio-Donahue C.A., Jané-Valbuena J., Johnson B.E., Lau K.S., Lively T., Mazzilli S.A., Pe'er D., Santagata S., Shalek A.K., Schapiro D., Snyder M.P., Sorger P.K., Spira A.E., Srivastava S., Tan K., West R.B., Williams E.H.; Human Tumor Atlas Network. The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution. *Cell* 181:236 (2020).

Albain K.S., Gray R.J., Makower D.F., Faghih A., Hayes D.F., Geyer C.E., Dees E.C., Goetz M.P., Olson J.A., Lively T., Badve S.S., Saphner T.J., Wagner L.I., Whelan T.J., Ellis M.J., Wood W.C., Keane M.M., Gomez H.L., Reddy P.S., Goggins T.F., Mayer I.A., Brufsky A.M., Toppmeyer D.L., Kaklamani V.G., Berenberg J.L., Abrams J., Sledge G.W., Sparano J.A. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. *JNCI* 113:390 (2021).